A Multicenter Phase II Trial of Intratumoral IL12 Plasmid Electroporation in Cutaneous Lymphoma.

Trial Profile

A Multicenter Phase II Trial of Intratumoral IL12 Plasmid Electroporation in Cutaneous Lymphoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Dec 2016

At a glance

  • Drugs Tavokinogene telsaplasmid (Primary)
  • Indications Cutaneous T cell lymphoma; Mycosis fungoides; Sezary syndrome
  • Focus Therapeutic Use
  • Sponsors OncoSec Medical
  • Most Recent Events

    • 02 Mar 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 16 Jun 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
    • 09 Apr 2014 Planned number of patients changed from 27 to 34.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top